Effect of tablets with a combination of telmisartan and amlodipine on patients with hypertension: The Cotalo study

Hypertension Research

Volumn 36, Issue 7, 2013, Pages 620-626

  Ohishi, Mitsuru ^a   Kawai, Tatsuo ^a   Hayashi, Norihiro ^b   Kitano, Shoichi ^c   Katsuya, Tomohiro ^d   Nagano, Masahiro ^e   Hirotani, Atsushi ^f   Yamamoto, Koichi ^a   Kamide, Kei ^a   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Wada Clinic   (Japan)

^c Nanko Hospital   (Japan)

^d Katsuya Clinic   (Japan)

^e Nagano Clinic   (Japan)

^f Hirotani Clinic   (Japan)

Author keywords

ambulatory blood pressure monitoring; amlodipine; fixed dose combination; metabolic syndrome; telmisartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS TELMISARTAN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; EVENING DOSAGE; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLIC SYNDROME X; MORNING DOSAGE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; EPINEPHRINE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TABLETS;

EID: 84881452147     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.10     Document Type: Article

References (30)

1. Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti AEuropean Society of Hypertension; European Society of Cardiology. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007; 16: 135-232.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
3. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-1529. (Pubitemid 32783749)
4. Neutel JM, Smith DHG. Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database. J Clin Hypertens 2003; 1: 58-63.
5. Kontny F, Risanger T, Bye A, Arnesen Ø, Johansen OE. TELMIMORE Study Investigators. Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care. Vasc Health Risk Manag 2010; 6: 31-38.
6. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50: 560-586.
7. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren JASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro-flumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. (Pubitemid 41265663)
8. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
9. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-719. (Pubitemid 47176510)
10. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407.
11. Neldam S, Lang M, Jones RTEAMSTA-5 Investigators. Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study. J Clin Hypertens 2011; 13: 459-466.
12. Hermida RC, Ayala DE, Fernández JR, Calvo C. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 2007; 50: 715-722. (Pubitemid 47442736)
13. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia PEuropean Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23: 697-701. (Pubitemid 40523262)
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
15. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M. Metabolic syndrome. J Atheroscler Thromb. 2008; 15: 1-5.
16. Mengden T, Binswanger B, Spühler T, Weisser B, Vetter W. The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens 1993; 11: 1403-1411. (Pubitemid 24008489)
17. Chavanu K, Merkel J, Quan AM. Role of ambulatory blood pressure monitoring in the management of hypertension. Am J Health Syst Pharm 2008; 65: 209-218. (Pubitemid 351220770)
18. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien EOffice versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-2415. (Pubitemid 36682819)
19. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913. (Pubitemid 35472129)
20. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156-161. (Pubitemid 40946507)
21. de la Sierra A, Banegas JR, Segura J, Gorostidi M, Ruilope LMCARDIORISC Event Investigators. Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study. J Hypertens 2012; 30: 713-719.
22. Cuspidi C, Sala C, Valerio C, Negri F, Mancia G. Nocturnal blood pressure in untreated essential hypertensives. Blood Press 2011; 20: 335-341.
23. Pierdomenico SD, Cuccurullo F. Ambulatory blood pressure monitoring in type 2 diabetes and metabolic syndrome: a review. Blood Press Monit 2010; 15: 1-7.
24. Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006; 66: 51-83. (Pubitemid 43148989)
25. Inoue T, Node K. Telmisartan as a metabolic sartan for targeting vascular failure. Expert Opin Pharmacother 2008; 9: 1397-1406. (Pubitemid 351877522)
26. Lindqvist M, Kahan T, Melcher A, Ekholm M, Hjemdahl P. Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. J Hypertens 2007; 25: 169-175. (Pubitemid 44885679)
27. Karas M, Lacourcière Y, LeBlanc AR, Nadeau R, Dubé B, Florescu M, Lamarre-Cliche M, Poirier L, Larochelle P, de Champlain J. Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients. J Hypertens 2005; 23: 1251-1260. (Pubitemid 40862730)
28. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-1654. (Pubitemid 126613653)
29. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 904-912. (Pubitemid 32163892)
30. Uresin Y, Erbas B, Ozek M, Ozkök E, Gürol AO. Losartan may prevent the elevation of plasma glucose, corticosterone and catecholamine levels induced by chronic stress. J Renin Angiotensin Aldosterone Syst 2004; 5: 93-96. (Pubitemid 39010817)